Clevidipine
Cleviprex (clevidipine) is a small molecule pharmaceutical. Clevidipine was first approved as Cleviprex on 2008-08-01. It is used to treat hypertension in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Cleviprex (discontinued: Cleviprex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clevidipine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLEVIPREX | Chiesi Farmaceutici | N-022156 RX | 2008-08-01 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cleviprex | New Drug Application | 2022-11-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| C9248 | Injection, clevidipine butyrate, 1 mg |
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | 9 | 5 | 2 | 18 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 2 | 1 | 2 | 1 | 6 |
| Emergencies | D004630 | — | — | — | — | 4 | 1 | — | 5 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | 1 | 3 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 2 | — | 1 | — | 3 |
| Aortic aneurysm | D001014 | EFO_0001666 | I71.9 | — | — | — | 1 | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 1 | — | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | 1 | — | 1 |
| Aortic diseases | D001018 | — | — | — | — | — | 1 | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malignant hypertension | D006974 | EFO_1001031 | — | — | — | 4 | — | — | 4 |
| Hypertensive crisis | D000096003 | — | — | — | — | 4 | — | — | 4 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 2 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 1 | 2 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | 1 | — | — | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | 1 | — | — | 1 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | 1 | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | 1 | — | — | 1 |
| Thrombectomy | D017131 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aneurysm | D000783 | HP_0002617 | I72.9 | — | 1 | — | — | 1 | 2 |
| Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | 1 | — | — | — | 1 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrectomy | D005743 | — | — | — | — | — | — | 1 | 1 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 1 | 1 |
| Dissection | D004210 | EFO_0003856 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clevidipine |
| INN | clevidipine |
| Description | Clevidipine is a dihydropyridine. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl |
Identifiers
| PDB | — |
| CAS-ID | 167221-71-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1237132 |
| ChEBI ID | — |
| PubChem CID | 153994 |
| DrugBank | DB04920 |
| UNII ID | 19O2GP3B7Q (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cleviprex – The Medicines Company
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 380 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
332 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use